Work

Effect of Weight Loss Amplitude Combined with Antiarrhythmic Drugs on Atrial Fibrillation Freedom, as compared to Catheter Ablation: A Sub-Analysis of the PRAGUE-25 Trial

Year: 2026
Type: article
Abstract: BACKGROUND AND AIMS: In the PRAGUE-25 study, the effect of lifestyle modification (LFM) in combination with antiarrhythmic drugs (AAD) in patients with atrial fibrillation (AF) and BMI 30-40 was smaller than that of catheter ablation (CA). The presented sub-analysis aims to assess the relationship between the actual weight reduction and the AF burden 12 months after randomization. METHODS: Per-protocol analysis of the PRAGUE-25 trial. Patients in the LFM+AAD group were stratified into tertiles based on the extent of relative weight reduction, and a comparison of AF burden was performed between the LFM+AAD tertiles and the CA group. RESULTS: The study analyzed 83 LFM+AAD patients (age 60 ±9 years, 31% women, 54% paroxysmal AF, mean weight 109±17 kg) and 99 CA patients (age 60±9 years, 32% women, 56% paroxysmal AF, weight 109±15 kg). Within the LFM+AAD group, 28 patients achieved a weight reduction of >8.3% (-15.46±6.16 kg), 27 patients were between 3.1-8.1% (-6.56±2.28 kg), and 28 patients were <3.1% (+1.38±4.03 kg). Compared to the CA group, the AF burden at 12 months (0 [IQR 0-0]) was significantly higher in the second (3.5% [0; 52] and third (1[0; 47] LFM-ADD tertiles, but did not differ from CA in the first tertile (0% [0; 11.], p=0.17). CONCLUSION: In obese patients, the maintenance of SR on AADs is related to the level of weight reduction. The efficacy of AADs in obese patients with a significant weight loss at 12-months follow-up is close to catheter ablation, although the overall AF burden is still non-significantly higher.
Source: EP Europace
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,909
OpenAlex ID: W7124862344
FWCI:
Cites:
Cited by:
Related to: